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Antimicrobial stewardship (AMS) plays a pivotal role in the fight 
against antimicrobial resistance. A fundamental tenet of AMS is dose 
optimisation, whereby appropriate usage ensures clinical benefit. Dose 
optimisation in practice requires specific knowledge of the agent, the 
patient and the pathogen involved. At present, efforts to dose-optimise 
are based largely on knowledge of the agent and patient, with less 
emphasis on the pathogen. Detailed knowledge of the pathogen and 
its susceptibility to a particular agent is seldom available or considered 
in dose-optimisation strategies. I wish to highlight the minimum 
inhibitory concentration (MIC) as a crucial determinant in dose-
optimisation strategies at the bedside and demonstrate the importance 
of MIC-guided antimicrobial therapy.
Antimicrobial susceptibility testing (AST) is a critical function 
of any microbiology laboratory, as it forms the basis upon which 
decisions on treatment of infectious diseases are made. The AST result 
provided on a laboratory report in the form of an S (susceptible), I 
(intermediate) or R (resistant) is derived from clinical breakpoints. 
Clinical breakpoints are in turn derived from analysis of the MIC value 
for a particular drug-bug combination. The MIC is defined as the 
lowest concentration of antibiotic required to inhibit visible growth 
of a micro-organism over a defined time interval. There is therefore 
a defined concentration of antimicrobial (MIC value) associated with 
the categorisation of an isolate as S, I or R. For example, an Escherichia 
coli isolate susceptible to ampicillin will have an MIC ≤8  µg/mL (as 
per European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) clinical breakpoints[1]). These MIC values are not routinely 
reported, but rather the categorisation (S/I/R) only. The reason that 
MICs are seldom reported has more to do with the AST methodology 
than anything else. The gold standard for MIC testing is broth 
microdilution (BMD) or agar dilution, methods not practically feasible 
for a routine diagnostic laboratory. Hence routine AST results are 
based on alternative methods that have been validated against the 
gold standard, which then extrapolate to the MIC with a reported 
categorisation (S/I/R). The categorisation (S/I/R) highlights those 
agents that are more likely to achieve a successful outcome (i.e. agents 
reported as susceptible). However, antimicrobial resistance is a relative 
phenomenon, as illustrated by the following clinical scenario: empirical 
treatment of a particular infectious disease with good clinical response, 
only to subsequently find that the pathogen isolated is reported resistant 
to the chosen empirical agent. The explanation for this is that resistance 
is relative, and owing to a multitude of other factors, principally related 
to drug exposure (see below), the antimicrobial was active against the 
isolated pathogen. This gives rise to the 90/60 rule in AST – 90% of 
patients treated with an antimicrobial that is reported as S will respond 
clinically, whereas only 60% of patients treated with an antimicrobial 
that is reported as R will respond clinically.[2] The most important 
factor responsible for this observation is the well-described influence 
of pharmacokinetic-pharmacodynamic (Pk-Pd) target optimisation. [3] 
This is illustrated by the example of an extended-spectrum beta-
lactamase (ESBL)-producing E. coli in urine reported as R to cefepime, 
yet the clinical response is favourable despite this. The high renal 
elimination of unchanged drug means that even at a low dose (250 mg) 
urinary concentrations of cefepime are ~90 - 190 µg/mL, well in excess 
of the clinical breakpoint of 1 µg/mL (EUCAST breakpoint).[1,4] In the 
era of multidrug resistance the reporting of isolates as simply ‘R’ when 
based on an MIC they may be therapeutic options results in limited 
antimicrobial choices, reliance on broad-spectrum agents and limited 
ability to tailor antimicrobial therapy to the individual.
Antimicrobial efficacy can be correlated with its particular Pk-Pd 
parameter. There are three defined Pk-Pd parameters: (i) percentage 
duration of time that free-drug concentration exceeds the MIC 
(%fT>MIC); (ii) the ratio of maximal drug concentration to MIC 
(Cmax:MIC); and (iii) the ratio of the area under the concentration-
time curve at 24 hours to MIC (fAUC0-24:MIC).
[5] The parameters of 
importance in determining efficacy as defined by the Pk-Pd target of an 
antimicrobial agent are therefore a function of drug exposure, which is 
largely determined by the dose administered and pharmacokinetics of 
the drug, and the MIC of the micro-organism. The clinical importance 
of this relationship has been demonstrated through correlation with 
clinical outcomes. The landmark DALI study[6] showed that for beta-
lactam agents, clinical outcome correlated with increasing %fT>MIC. 
The pivotal role of the MIC was further highlighted in this study, where 
a positive clinical outcome was 2.3 times more likely for pathogens with 
an MIC ≤2 µg/mL. Knowledge of the MIC allows for more tailored 
antimicrobial therapy through improved choice of agent guided by an 
understanding of the pathogen and its MIC distribution, and (through 
application to simulated pharmacological data) the likely probability of 
Pk-Pd target attainment.
Despite the importance of the MIC, it is seldom considered in efforts 
to dose-optimise. This stems primarily from lack of awareness of its 
importance and knowledge of how to interpret MIC-based AST results, 
and the limited availability of this type of testing. We have developed 
capacity for gold-standard MIC-based AST that was driven largely by 
a need to compare generic with originator antimicrobial compounds. 
These comparative MIC studies are in vitro studies comparing the 
MIC of the originator with that of the generic against a collection 
of clinically relevant isolates using BMD, the current gold standard. 
Although relatively simple and devoid of significant scientific merit, 
the studies were born out of a need for justification, reassurance and 
quality control. It is reassuring to note that all generic manufacturers 
willing to subject their product to this comparative evaluation 
have demonstrated excellent in vitro microbiological efficacy and 
compliance with accepted concordance thresholds. More importantly, 
however, these studies have highlighted the importance of MIC testing. 
Table 1 provides an example of the valuable information provided 
by MIC testing. It highlights significant differences in ciprofloxacin 
susceptibility between two distinct phenotypic groups of Klebsiella 
pneumoniae isolates. Despite the equivalence in overall susceptibility 
rates, the MIC data demonstrate a marked elevation (>10-fold) in 
MIC for ESBL-producing isolates. This has important implications 
for dose optimisation given the concentration-dependent nature of 
ciprofloxacin activity.
AMS is at present a global and national priority. It is considered a 
strategic objective of our national antimicrobial resistance framework 
and is a current metric in many hospitals.[7] AMS is defined as 
‘coordinated interventions designed to improve and measure the 
appropriate use of antibiotic agents by promoting the selection of the 
optimal antibiotic drug regimen, including dosing, duration of therapy 
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and route of administration’.[8] Dose optimisation is considered crucial, 
and an MIC (which I have already argued is a critical determinant of 
antimicrobial selection and dosing) therefore becomes synonymous 
with good AMS. Yet the role of laboratories in providing MIC data 
and MIC-based AST has largely been ignored and the majority of 
clinical decisions at the bedside rely solely on a categorical (S/I/R) 
interpretation. I do not advocate that treatment of every infectious 
disease process requires an MIC. This is too onerous for current 
laboratory capacity and is not necessary, as clinical breakpoints (by 
virtue of the ‘90/60 rule’) allow for sufficient leeway. It does, however, 
require broad-scale consideration for when an MIC is required (at 
clinician and clinical microbiologist level) and how best to extract 
MIC-guided therapeutic decisions from currently employed AST 
methods (pathologist level).
Addressing the first requirement is relatively simple from an 
indication perspective, although widespread education is required 
to create awareness of this need. Any infectious disease where dose 
optimisation in the form of a tailored antimicrobial regimen is required 
would fulfil the criterion for MIC-based AST. This would include all 
significant infections in critically ill patients and the so-called ‘difficult-
to-treat’ infections, e.g. osteomyelitis, periprosthetic joint infections, 
infective endocarditis, etc. The second requirement is substantially 
more challenging for laboratories owing to limitations imposed by 
routine diagnostic AST systems (discussed above). Additional MIC 
testing of isolates against targeted antimicrobials could be performed 
based on predefined criteria such as source of specimen (e.g. blood) or 
location of patient (e.g. intensive care unit). This would require careful 
consideration by all stakeholders including policy-makers and funders. 
However, it will not account for all relevant scenarios, and close liaison 
between clinician and microbiologist would still be required to direct 
AST accordingly. A second possibility is to utilise current commercial 
systems based on more rigorous evaluation. The Vitek system 
(Biomerieux, South Africa (SA)) is currently used by the majority of 
diagnostic laboratories in SA and is capable of providing MICs. There 
is a concern among clinical microbiologists that these MICs (which 
are extrapolated from growth curves using sophisticated software) are 
not true MICs, and they have therefore not been reported routinely. 
There is some merit to this concern, although the requirements for 
approval by various regulatory authorities (including the US Food 
and Drug Administration) have been met and the system is therefore 
capable of providing MIC data that fulfil the essential agreement 
criteria (i.e. MIC within one two-fold dilution of the reference method-
derived MIC).[9] Importantly, any MIC value actually represents a 
range given the artificially created two-fold dilution scheme, and the 
precision associated with AST can vary by drug-bug combination. 
Through inter- and intra-laboratory comparative analysis utilising 
BMD and available MIC susceptibility data, it is possible to characterise 
isolates as being wild type (no acquired resistance mechanism) and to 
delineate the range of MICs based on specific phenotypes. The current 
Vitek AES software system already does this and many laboratories are 
reliant on it. This allows reporting of MICs with a sufficient degree 
of confidence and enables further directed MIC testing that is either 
guided clinically or based on a validated laboratory protocol. There is 
no one-size-fits-all approach to this methodology, so laboratories are 
required to evaluate their own isolates and systems. The advantage 
is that MIC-based AST becomes feasible in a routine diagnostic 
laboratory with provision of information that can better guide 
therapeutic decisions at the bedside.
The ensuing challenge is interpretation of MIC-based AST results, 
as we are accustomed to categorical interpretation only. The role of 
the clinical microbiologist becomes crucial in providing the necessary 
guidance in interpretation and selection of appropriate therapy. 
Clinical microbiologists themselves would need to become more 
familiar with MIC-based AST and the use of these data in guiding 
antimicrobial decisions. The information provided on microbiology 
reports should be more detailed, and we need to interrogate the reports 
with more vigour. The realisation that a simple AST categorisation 
may no longer suffice for each and every patient is a critical next step 
in ensuring dose optimisation. The role of MIC-based AST should 
be placed high on the agenda of AMS initiatives, with sustained 
education platforms aimed at addressing the current knowledge gap. 
Furthermore, there needs to be a focused drive by all laboratories to 
move to the EUCAST AST system following a 2015 national decision 
to adopt the EUCAST guidelines. The EUCAST guidelines provide 
robust, clinically relevant breakpoints supported by substantial MIC 
data that are freely available (www.eucast.org), thereby supporting and 
facilitating the implementation of MIC-based AST results.
The importance of the MIC in guiding therapeutic decisions for 
‘difficult-to-treat’ infections cannot be overstated. The growing body 
of literature supports a move towards individualised and tailored 
antimicrobial therapy.[10] This requires knowledge of the Pk-Pd 
parameters associated with clinical efficacy of an antimicrobial, which 
in turn creates a need for an MIC correlate given its direct relationship 
to these parameters. Furthermore, improved diagnostic determinants 
of drug exposure in each individual patient are required and this can 
only be attained through therapeutic drug monitoring (TDM). Only 
when armed with both an MIC and a drug level (TDM), taking into 
consideration the Pk-Pd correlate for a particular antimicrobial, will 
we truly be able to dose-optimise antimicrobial therapy and achieve 
the desired AMS outcomes.
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Table 1. Ciprofloxacin susceptibility of Klebsiella pneumoniae comparing the MIC values of ESBL-producing v. non-ESBL-
producing isolates
MIC50 (µg/mL) MIC90 (µg/mL) Susceptible* (%)
Non-ESBL-producing K. pneumoniae (n=11) ≤0.015 ≤0.015 90.9
ESBL-producing K. pneumoniae (n=35) 0.25 0.5 90.9
MIC = minimum inhibitory concentration; MIC50 and MIC90 = the MIC for 50% and 90% of isolates tested; ESBL = extended-spectrum beta-lactamase.
*Susceptible based on the 2017 Clinical Laboratory Standards Institute breakpoint of ≤1 µg/mL.
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